Repurposing bunamidine hydrochloride as a potent antimicrobial agent targeting vancomycin-resistant Enterococcus membranes

Pengfei She, Guanqing Huang, Shaowei Guo, Dan Xiao, Yiqing Liu, Mengna Li, Lihua Lu, Hong Yuan, Yimin Li, Linying Zhou, Yong WumSystems 2025 · DOI

TL;DR

Vancomycin-resistant Enterococci (VRE) are a growing threat, and current treatments are limited. This study repurposes bunamidine hydrochloride (BUN), an antiparasitic drug, as a potent new antimicrobial against VRE. BUN effectively kills VRE by disrupting their cell membranes, works against biofilms, and shows promising efficacy and safety in animal models.

What Problem Does This Paper Address?

The rise of antibiotic-resistant bacteria, particularly Vancomycin-Resistant Enterococci (VRE), is a major global health crisis. VRE infections are difficult to treat due to limited therapeutic options and rapid resistance development. Conventional antibiotics often target essential bacterial processes, but bacteria have developed sophisticated resistance mechanisms. This has led to a search for alternative strategies, with targeting bacterial cell membranes emerging as a promising avenue. Bacterial membranes are crucial for cell integrity and function, and are less conserved between bacteria and human cells, offering a potential for selective toxicity. However, developing new membrane-targeting agents is challenging. This paper addresses the need for new VRE treatments by exploring the repurposing of existing drugs, specifically bunamidine hydrochloride (BUN), an antiparasitic agent, for its potential antimicrobial activity against VRE.

Methods

The researchers employed a multi-faceted approach to investigate BUN's antimicrobial activity and mechanism:

  • Antimicrobial Susceptibility Testing: Standard microdilution methods were used to determine Minimum Inhibitory Concentrations (MICs) and Minimum Bactericidal Concentrations (MBCs) against VRE and VSE strains.
  • Bactericidal Dynamics: Time-killing assays were performed to assess the rate of bacterial killing by BUN.
  • Live/Dead Staining: SYTO9/Propidium Iodide (PI) staining and confocal laser scanning microscopy (CLSM) were used to visualize and quantify live and dead bacterial cells, indicating membrane integrity disruption.
  • Membrane Potential and Permeability Assays: The dye DiSC3(5) was used to measure membrane potential depolarization, and SYTOX Green was used to assess membrane permeability changes.
  • Ultrastructural Observation: Scanning Electron Microscopy (SEM) and Transmission Electron Microscopy (TEM) were used to visualize morphological changes in bacterial cells treated with BUN.
  • Biofilm Assays: Crystal violet staining and XTT assays were used to assess BUN's ability to inhibit biofilm formation and eradicate pre-formed biofilms. CLSM was also used for biofilm visualization.
  • Resistance Induction Assays: Stepwise and single-step resistance induction assays were performed to evaluate BUN's potential to induce bacterial resistance.
  • Post-Antibiotic Effect (PAE) Assay: This assay measured the duration of BUN's inhibitory effect after its removal.
  • Molecular Dynamics (MD) Simulations: MD simulations were used to model the interaction of BUN with bacterial and mammalian cell membranes at a molecular level, investigating its binding affinity and mechanism of interaction with phospholipids.
  • Cell Viability and Apoptosis Assays: CCK-8 assays, Annexin V-FITC/PI staining, and Calcein-AM/PI staining were used to assess BUN's cytotoxicity and potential to induce apoptosis in human cell lines (HSF and HaCaT).
  • In Vivo Efficacy Models: Mouse subcutaneous abscess and wound infection models were used to evaluate BUN's efficacy in reducing bacterial burden and promoting wound healing.
  • Pharmacokinetic (PK) Analysis: BUN's absorption, distribution, metabolism, and excretion were studied in mice.

Datasets

Not discussed in the paper.

Key Insights and Ideas

  • Drug Repurposing Success: BUN, an existing antiparasitic, shows significant promise as an antimicrobial against VRE, demonstrating the value of drug repurposing for combating antibiotic resistance.
  • Selective Membrane Targeting: BUN appears to preferentially target bacterial cell membranes, specifically interacting with phosphatidylglycerol (PG), a phospholipid abundant in bacteria but scarce in mammalian cells. This selectivity is key to its potential for low host cell toxicity.
  • Rapid and Potent Bactericidal Action: BUN exhibits rapid killing of VRE, significantly reducing bacterial viability within hours, distinguishing it from some bacteriostatic agents.
  • Effective Against Biofilms and Persister Cells: BUN demonstrates efficacy against VRE biofilms and persister cells, which are notoriously difficult to eradicate and contribute to treatment failure. This is a critical advantage over many conventional antibiotics.
  • Low Resistance Potential: BUN showed a very low propensity to induce bacterial resistance in both stepwise and single-step assays, a significant advantage compared to many existing antibiotics.
  • Distinct Mechanism of Action: BUN's mechanism involves membrane depolarization and increased permeability, leading to cell lysis, but it appears to do so through progressive disruption rather than rapid pore formation like some other membrane-active agents.

Key Results

  • BUN exhibited potent bactericidal effects against both VRE and vancomycin-susceptible enterococci (VSE), with MICs ranging from 2 to 4 µg/mL.
  • BUN significantly inhibited biofilm formation and eradicated biofilm-embedded persister cells.
  • In vivo studies in mouse models showed that BUN effectively reduced bacterial burden in subcutaneous abscesses and promoted wound healing in infected wounds.
  • BUN demonstrated low cytotoxicity in human cell lines, with IC50 values significantly higher than its MIC against VRE.
  • MD simulations revealed BUN's preferential interaction with bacterial-like membranes rich in PG analogs, leading to membrane destabilization.
  • BUN showed a prolonged post-antibiotic effect (PAE), suggesting sustained antibacterial activity.

Limitations and Future Work

  • Systemic Therapy Limitations: The PK profile of BUN in mice suggests rapid plasma clearance and moderate systemic exposure, which might limit its use for systemic therapy. Further studies are needed to optimize dosing regimens or develop advanced formulations.
  • Mechanistic Nuances: While BUN's membrane-disrupting mechanism is established, further investigation into its precise interactions and the specific nature of the progressive depolarization and permeability alteration is warranted.
  • Broader In Vivo Models: While promising, further studies are needed to evaluate BUN's efficacy in additional in vivo infection models.
  • Long-Term Toxicity: The in vitro apoptosis assessment was conducted over 24 hours, reflecting a standard acute toxicity assessment. Longer incubation periods or chronic dosing models would be valuable for a comprehensive evaluation of long-term cytotoxicity and safety in human cells.
  • Clinical Translation: While promising, BUN requires further development and clinical trials to confirm its safety and efficacy in humans for treating VRE infections.

Summary updated

Abstract

The global rise of vancomycin-resistant enterococci (VRE) poses serious challenges in clinical treatment due to limited therapeutic options and rapid resistance development. This study identifies bunamidine hydrochloride (BUN), a previously approved antiparasitic agent, as a potent membrane-targeting antimicrobial with rapid bactericidal activity against both planktonic and biofilm-associated VRE. By selectively interacting with bacterial phosphatidylglycerol, BUN disrupts membrane integrity and inhibits persister cells, while maintaining low cytotoxicity and high <i>in vivo</i> efficacy in murine infection models. Our findings highlight the potential of drug repurposing strategies to accelerate the discovery of effective antibiotics and provide a promising candidate for future clinical management of multidrug-resistant bacterial infections.
BibTeX
@inproceedings{she2025repurposing,
  author = {Pengfei She and Guanqing Huang and Shaowei Guo and Dan Xiao and Yiqing Liu and Mengna Li and Lihua Lu and Hong Yuan and Yimin Li and Linying Zhou and Yong Wu},
  title = {{Repurposing bunamidine hydrochloride as a potent antimicrobial agent targeting vancomycin-resistant <i>Enterococcus</i> membranes}},
  booktitle = {mSystems},
  year = {2025},
  doi = {10.1128/msystems.00425-25},
}
Figure